Gubra A/S

07/10/2025 | Press release | Distributed by Public on 07/10/2025 14:15

Reporting of transactions made by persons discharging managerial responsibilities and persons closely associated with them in Gubra A/S' shares

Social share for Facebook Social share for Twitter/X Social share for LinkedIn Social share for Bluesky Share with Email
Published: 2025-07-10 22:14:00 CEST Gubra A/S - Managers' Transactions

Reporting of transactions made by persons discharging managerial responsibilities and persons closely associated with them in Gubra A/S' shares

Pursuant to the Market Abuse Regulation article 19, Gubra A/S, CVR no. 30514041 (the "Company") hereby notifies receipt of information of the following transactions made by persons discharging managerial responsibilities in the Company and persons closely associated with them in the Company's shares and other financial instruments linked thereto.

1. Details of the person discharging managerial responsibilities/person closely associated
a) Name Kristian Borbos
2. Reason for the notification
a) Position/status Chief Financial Officer
b) Initial notification/ Amendment Initial notification
3. Details of the issuer, emission allowance market participant, auction platform, auctioneer or auction monitor
a) Name Gubra A/S
b) LEI 254900T17RRFZONO6W53
4.1 Details of the transaction(s):
a) Description of the financial instrument, type of instrument Warrants related to the shares of Gubra A/S

Identification code Shares (ISIN DK0062266474)
b) Nature of the transaction Warrants granted free of charge in connection with the Company's incentive programme.
c) Price(s) and volume(s) Price(s) Volume(s)
DKK 0 6,385
d) Aggregated information
- Aggregated volume
- Price
Average price per share: DKK 0
Total number of shares: 6,385
Total price: DKK 0
e) Date of the transaction 8 July 2025
f) Place of the transaction Outside a trading venue

Contacts at GubraMedia: Sofia Pitt Boserup, sbo@gubra.dk, +45 4188 9586Investors: Kristian Borbos, kbo@gubra.dk, +45 3080 8035

About GubraGubra, founded in 2008 in Denmark, listed on Nasdaq Copenhagen, is specialized in pre-clinical contract research services and peptide-based drug discovery within metabolic and fibrotic diseases. Gubra's activities are focused on the early stages of drug development and are organised in two business areas - CRO Services and Discovery & Partnerships (D&P). The two business areas are highly synergistic and create a unique entity capable of generating a steady cash flow from the CRO business while at the same time enjoying biotechnology upside in the form of potential development milestone payments and potential royalties from the D&P business. Gubra has approx. 270 employees and in 2024 revenue of DKK 266 million. See https://www.gubra.dk for more information.

This information is information that Gubra is obliged to make public pursuant to the EU Market Abuse Regulation. The information was submitted for publication, through the agency of the contact persons set out above, at 2025-07-10 22:14 CEST.

Reporting of transactions made by persons discharging managerial responsibilities and persons closely associated with them in Gubra AS shares.pdf https://attachment.news.eu.nasdaq.com/ac0eb6772c528b4e25a3c579980c52d27
Company News Subscribe European Market Activity Nasdaq Europe
© 2025, Nasdaq, Inc. All Rights Reserved.
Gubra A/S published this content on July 10, 2025, and is solely responsible for the information contained herein. Distributed via Public Technologies (PUBT), unedited and unaltered, on July 10, 2025 at 20:15 UTC. If you believe the information included in the content is inaccurate or outdated and requires editing or removal, please contact us at support@pubt.io